PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsmyeloid leukemia
MeSH D007951 - myeloid leukemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D007938:Leukemia
130 Companies
21 Drugs
$
Success rate
D007951: 
Myeloid leukemia
26 Companies
8 Drugs
$
Success rate
D015464:Bcr-abl positive chronic myelogenous leukemia
47 Companies
13 Drugs
$
Success rate
D015470:Myeloid leukemia acute
51 Companies
17 Drugs
$
Success rate
D015477:Myelomonocytic leukemia chronic
17 Companies
1 Drug
$
Success rate
D015479:Myelomonocytic leukemia acute
2 Companies
1 Drug
$
Success rate
D023981:Myeloid sarcoma
0 Companies
0 Drugs
Success rate
D054429:Myelomonocytic leukemia juvenile
0 Companies
0 Drugs
Success rate
D054438:Leukemia myeloid chronic atypical bcr-abl negative
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaImatinib Imatinib  2016-08-04   
Imatinib Imatinib Teva  2013-01-07   
Imatinib Imatinib Teva B.V  2017-11-15   
MylanImatinib Imatinib  2017-06-21   
Johnson & JohnsonDecitabine Dacogen  2012-09-20   
NovartisImatinib Gleevec  2001-05-10 $887 M Q2/20-Q2/23 
Imatinib Glivec  2001-11-07   
Asciminib Scemblix 2033-05-13 2021-10-29 $301 M Q2/22-Q2/24 
PfizerBosutinib Bosulif  2013-03-27 $645 M Y2023 
TakedaPonatinib Iclusig 2026-12-22 2012-12-14   
Dr Reddys LaboratoriesImatinib Imatinib  2018-08-13   
Zydus TherapeuticsImatinib Imatinib  2020-04-08   
Sun Pharmaceutical IndustriesImatinib Imatinib  2015-12-03   
ApotexDasatinib Dasatinib  2016-06-10   
Imatinib Imatinib  2016-08-05   
Ponatinib Ponatinib  2023-07-14   
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
60%
32/53
Phase 2
44%
27/62
Phase 3
24%
9/37
Approved: 7Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Imatinib,
Imatinib mesylate,
Ademetionine,
Aspartame,
Bevifimod,
Manitol,
Sti571,
Evidence
Johnson & Johnson
Decitabine,
Tipifarnib,
Aspartame,
CUSATUZUMAB,
Doxecitine,
Talacotuzumab,
Deoxycytidine,
Hsct,
Sti571,
Arm1,
Arm2,
Abt199
Novartis
Imatinib,
Imatinib mesylate,
Asciminib,
Antithrombin iii,
Magrolimab,
Cilmostim,
Sabatolimab,
Spartalizumab,
Lenograstim,
Dovitinib,
Mitoguazone,
Ademetionine,
Vatalanib,
Aprinocarsen,
Calcium dobesilate,
Regramostim,
Gemtuzumab,
Molgramostim,
SIREMADLIN,
Sodium lactate,
Albinterferon alfa-2b,
Aspartame,
Bevifimod,
Doxecitine,
Quilizumab,
Microcrystalline cellulose,
Retinol,
Deoxycytidine,
Anthracycline,
Vob560,
Dnr,
Magnolia,
MIK665,
Vp16,
Magma,
Sagramostim,
Triapine,
Hsct,
Sti571,
Arm1,
Arm2,
IDH305,
Evidence,
Abt199
Pfizer
Bosutinib,
Lampalizumab,
Etrolizumab,
Lenograstim,
Ademetionine,
Gemtuzumab,
Bevifimod,
FILANESIB,
Ag013736,
Anthracycline,
Dnr,
Magnolia,
Vp16,
Gcsf,
Magma,
Pd0332991,
Triapine,
Hsct,
KSP,
Sti571,
Bolus,
Evidence,
Abt199
Takeda
Ponatinib,
Pevonedistat,
Alisertib,
Bevifimod,
Muromonab-cd3,
GDX012,
Abt199
Apotex
Imatinib,
Imatinib mesylate
Amneal Pharmaceuticals
Imatinib,
Imatinib mesylate,
Bevifimod,
Sti571
Bristol Myers Squibb
Dasatinib,
Antithrombin iii,
Calcium dobesilate,
Sodium lactate,
Aspartame,
Bevifimod,
ULOCUPLUMAB,
Microcrystalline cellulose,
Allograft,
Solumedrol,
Triapine,
Hsct,
Ptcy,
Sti571,
Arm1,
Arm2,
Evidence,
Abt199
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use